Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||15/12/2020|
|Rapid review completed||13/01/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that nivolumab not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.